Drug Sensitivity Testing for Cancer Therapy, Technique Analysis and Trends.

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Drug sensitivity testing (DST) has undergone rapid advancements in the last two decades.
• Progress in DST is driven by technical innovations enhancing speed, throughput, sensitivity, and reducing tumor sample requirements.
• Biomedical knowledge and technical progress in DST have a mutually supportive relationship.

Purpose of the Study:

• To highlight medicinal and technical insights into drug sensitivity testing (DST) for anticancer treatment.
• To discuss the evolution of DST systems and their impact on clinical practice.
• To identify future directions for DST development to address complex therapeutic challenges.

Main Methods:

• Review of technical advancements in DST systems, including improvements in speed, throughput, sensitivity, and sample volume.
• Analysis of the interplay between biomedical knowledge and technological progress in DST.
• Examination of the clinical implications of advanced DST, such as increased sample processing capacity.

Main Results:

• DST systems have evolved to become faster, more sensitive, and capable of analyzing smaller tumor quantities.
• Technical strides have enabled DST to enter a new clinical phase, processing over 500 samples with minimal tumor cells.
• Advanced DST resolves many pharmacological controversies and supports personalized medicine approaches.

Conclusions:

• DST is a critical drug selection system that requires further evolution to adapt to diverse clinical scenarios and tumor types.
• Enhanced understanding of cancer biology, including heterogeneity, plasticity, metastasis, and drug resistance, is essential for DST development.
• High-quality DST systems are vital for improving cancer patient treatment outcomes through precise drug selection.